Organization Profile

You just read:

Oncothyreon Announces Initiation of Phase 1 Trial of ONT-380 in Combination with Trastuzumab in Patients with Brain Metastases from HER2+ Breast Cancer

News provided by

Oncothyreon Inc.

Sep 03, 2013, 08:05 ET